NASDAQ$DCTH
Delcath Systems Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported $7.8 million in quarterly revenue.
Delcath Systems reported a significant increase in revenue for the second quarter of 2024, driven by sales of HEPZATO KIT™ and CHEMOSAT. The company is focused on expanding the adoption of HEPZATO KIT and advancing its clinical programs.
- Recognized second quarter revenue of $6.6 million from HEPZATO KIT and $1.2 million from CHEMOSAT sales.
- Activated three HEPZATO KIT treating centers in the US during the second quarter, with an additional center in July, totaling eight active centers.
- Received New Technology Add-on Payment status (NTAP) for HEPZATO from CMS effective August 1, 2024.
- Submitted the final principal payment due to Avenue Venture Opportunities Fund, L.P. on August 1, 2024.
Headline financials
Revenue & EPS history
Delcath · Revenue · Quarterly
$7.77M
Forward guidance
Delcath is optimistic about the continued adoption of HEPZATO KIT and its potential as a key therapeutic approach for metastatic uveal melanoma patients.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-2.1%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+7.7%
Avg return
30 days after
28%
9 / 32 earnings
Positive
+37.5%
Q2 2019
Best reaction
-26.4%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.3% | +0.6% | -5.3% | |
| Q4 2025 | -11.7% | -15.8% | -12.1% | |
| Q3 2025 | -4.7% | -9.2% | +5.3% | |
| Q1 2025 | +23.6% | +31.7% | +41.1% | |
| Q4 2024 | -1.6% | -12.1% | -18.0% | |
| Q3 2024 | -9.0% | -14.0% | +8.5% | |
| Q2 2024 | -2.6% | -4.2% | +33.7% | |
| Q1 2024 | +33.1% | +40.2% | +37.4% | |
| Q4 2023 | +9.2% | +2.4% | +12.9% | |
| Q3 2023 | -23.7% | -16.9% | +10.0% | |
| Q2 2023 | -20.6% | -23.3% | +18.2% | |
| Q1 2023 | +0.2% | +7.8% | +14.9% | |
| Q4 2022 | +22.3% | +18.8% | +17.6% | |
| Q3 2022 | -6.7% | +0.0% | +11.3% | |
| Q2 2022 | -2.3% | +10.2% | -5.4% | |
| Q1 2022 | -11.9% | -16.7% | -28.1% | |
| Q4 2021 | +1.3% | +2.8% | +0.0% | |
| Q3 2021 | -1.8% | -5.0% | -28.1% | |
| Q2 2021 | -11.8% | -13.5% | +1.1% | |
| Q1 2021 | -7.0% | -0.6% | +9.8% | |
| Q4 2020 | -24.8% | -7.2% | -31.8% | |
| Q3 2020 | +0.6% | +3.6% | +36.7% | |
| Q2 2020 | -2.6% | -4.6% | -9.3% | |
| Q1 2020 | -5.2% | -5.2% | +0.5% | |
| Q4 2019 | +0.0% | +13.8% | +55.7% | |
| Q3 2019 | -4.3% | -4.3% | -15.2% | |
| Q2 2019 | +37.5% | +27.5% | +26.2% | |
| Q1 2019 | -11.2% | +0.0% | +22.5% | |
| Q4 2018 | -6.5% | -8.9% | -35.5% | |
| Q3 2018 | -26.4% | -0.3% | -5.6% | |
| Q2 2018 | +0.0% | +19.0% | +78.8% | |
| Q1 2018 | +2.4% | +0.3% | -0.6% | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro